Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Glycotest, a UK-based liver disease diagnostics spinout of Baruch S. Blumberg Institute and Drexel University, has received $6m of its $10m series A commitment from drug developer Fosun Pharma after securing the second $3m tranche. The cash will go towards preparing for the US commercial launch of Glycotest’s algorithm-powered biomarker test for early-stage hepatocellular carcinoma, with Fosun’s final $4m series A contribution due on completion of certain development milestones. Fosun Pharma’s investment was first announced in October 2018 and,…
